CGTX News & Events

"We filed a request to meet with the Food and Drug Administration's Division of Psychiatry to discuss our plans for a registrational study in people with dementia with Lewy body psychosis," stated Lisa Ricciardi, Cognition's president and CEO. "We recently received our meeting invitation for May 20, 2026 and we are looking forward to a productive conversation so we can continue to move zervimesine forward in this important indication."

Cognition Therapeutics presented an analysis from the Phase 2 COG1201 SHIMMER study of zervimesine in dementia with Lewy bodies, or DLB, at the AD/PD 2026 Alzheimer's & Parkinson's Diseases Conference. The analysis focuses on Zervimesine's treatment effects on the behavioral and psychiatric symptoms most commonly associated with DLB. Zervimesine treatment resulted in an 86% slowing of decline on NPI-12 vs placebo in that Phase 2 study. This slowing of decline reflects zervimesine's disease-modifying mechanism of action. Cognition believes zervimesine has the potential to slow DLB progression and reduce the progression of its associated neuropsychiatric symptoms. Its unique mechanism should also allow zervimesine to be used in DLB patients who cannot tolerate traditional antipsychotics and benzodiazepines. Unlike traditional antipsychotics, zervimesine demonstrated a directionally favorable impact on cognitive fluctuations, memory, movement symptoms, and activities of daily living.

Cognition Therapeutics announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration, FDA, pertaining to the Type C meeting that was conducted on January 21, 2026.